Projects

The two founders, Drs. Hank Juo and Christine Liang, published a series of landmark studies in Investigative Ophthalmology & Visual Science (IOVS) in 2011, 2012, and 2022 to demonstrate how miR-328 is related to myopia development, and how miR-328 inhibitor may be used for myopia control in pediatric subjects. The proprietary microRNA therapeutic eye drops, SHJ002, was first tested in healthy children in the first-in-human (FIH) Phase-1 trial. This FIH trial was completed in 2021 and it also successfully showed the safety and tolerability of SHJ002 eye drops in children. In 2024, Sunhawk Vision Biotech received authorization from both US FDA and Taiwan FDA to conduct Phase 2 clinical trial to further evaluate the therapeutic effect on myopia control in young children.